Regeneron and Tessera Therapeutics Partner to Develop in-Vivo Gene Editing Therapy TSRA-196 for Alpha-1 Antitrypsin Deficiency

December 1, 2025 — Regeneron Pharmaceuticals announced today a global collaboration with Tessera Therapeutics to develop and commercialize Tessera’s investigational in-vivo gene editing therapy TSRA-196 targeting Alpha-1 Antitrypsin Deficiency (AATD). Under the agreement, Regeneron provides an upfront payment and equity investment totaling USD 150 million, while both companies will share global development costs and future commercialization profits. Additional milestone payments are also included contingent on development progress.

Photo by National Cancer Institute on Unsplash

TSRA-196 leverages Tessera’s proprietary Gene Writing™ platform combined with a non-viral delivery system to correct the underlying SERPINA1 gene mutation in one administration, aiming for a durable restoration of functional alpha-1 antitrypsin (AAT). Preclinical studies in mice and non-human primates have demonstrated high liver editing specificity and favorable tolerability, with no off-target effects reported.

This partnership is viewed as a significant step forward for AATD treatment and for the broader field of in-vivo gene writing therapies. If clinical development and regulatory review succeed, TSRA-196 has the potential to become one of the first commercially available therapies to cure a genetic disease via a one-time in-vivo gene editing intervention.

Photo by Diane Serik on Unsplash

Source: Regeneron & Tessera Therapeutics Press Release, Regeneron and Tessera to Jointly Develop TSRA-196 in-Vivo Gene Editing Therapy for AATD, December 1, 2025